острый промиелоцитарный лейкоз

The private residence costs{stands} research ICON-3 in which 2039 patients Ic-IV with stages of a cancer яичников have taken part. In control group patients received карбоплатин in doze AUC> 5 or combination САР (500/50/50 mg / m2), in compared group - a combination цисплатина and паклитаксела (75/175 mg / m2). Treatment was carried out{was spent} each 3 weeks in volume of 6 rates. The preliminary data testify that time before progressing and general life expectancy was identical irrespective of used chemotherapy. Sick (57 %) in group карбоплатина and CAP received the majority таксаны as chemotherapy of the second line that explains rather good remote results. Подробнее...

Thus, today in our disposal there is a lot of effective preparations and modes for treatment of patients by the widespread cancer яичников. As the first line of chemotherapy it is possible to use the combined modes (карбоплатин-паклитаксел, цисплатин-паклитаксел, карбоплатин-доцетаксел or CAP) or monotherapy by preparations of platinum (цисплатин 100 mg / m2 each 3 weeks of 6 rates or 50 mg / m2 weekly within 9 weeks, карбоплатин AUC x 5-7 each 3-4 weeks of 6 rates). The patients who have received at the first stage of treatment modes without inclusion таксанов, should receive necessarily таксаны in the second line of chemotherapy. At purpose{assignment} of the above-stated preparations and combinations in full dozes and recommended intervals it is possible to expect for reception of average time before progressing 15-17 months and average life expectancy of 30-36 months. Подробнее...